Technologies useful for clinical research in inhaled and nasal drug delivery development
Cough, a common adverse event in orally inhaled drugs and measure of treatment efficacy, is typically only assessed subjectively through patient self-reporting. Strados Labs FDA-cleared RESP® Biosensor enables drug developers to objectively monitor cough in daily life, providing a more complete picture of treatment response. The RESP® Biosensor collects granular metrics on cough including 24 hour frequency, intensity and bouts as well as novel insights such as wheezing and crackles.
Would you like to list your company in this section or upgrade your existing listing? For information about supplier listing options, click here.